Research
Hormonal
GLP-1 receptor agonists provide cardiovascular benefits, including reduced blood pressure and improved endothelial function, which may occur independently of weight loss.
GLP-1 receptor agonists offer cardiovascular protection beyond just weight loss. They can lower blood pressure and improve blood vessel function, likely through direct effects on the kidneys and blood vessels. These benefits may start appearing within weeks of treatment, even before significant weight loss occurs.
ModerateSupportsMEDIUM confidence
In clinical studies, reduction in blood pressure with GLP-1 receptor agonists tends to occur early on during treatment (after 2 weeks), before significant weight loss is observed, which suggests that these agents have direct hypotensive effects, and that reduction of blood pressure is not due to weight loss alone.
Why this rating
Based on meta-analyses and retrospective studies; long-term outcome trials were ongoing at publication.
Source
<scp>GLP</scp>‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Donna H. Ryan et al. · Obesity · 2015
DOI 10.1002/oby.21107
narrative_reviewCited 108×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (specifically liraglutide 3.0 mg) produce clinically significant weight loss in overweight or obese individuals through reduced appetite and energy intake, rather than increased energy expenditure.Good
- GLP-1 receptor agonists exhibit neuroprotective effects in animal models of Alzheimer's and Parkinson's disease, potentially by crossing the blood-brain barrier and reducing amyloid-beta accumulation.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →